Ekso Bionics (EKSO) Expected to Announce Earnings on Monday

Ekso Bionics (NASDAQ:EKSO) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Ekso Bionics to post earnings of ($0.08) per share and revenue of $5.0260 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:00 PM ET.

Ekso Bionics Trading Down 9.1%

Shares of NASDAQ:EKSO opened at $11.18 on Monday. The business’s 50-day moving average is $8.30 and its 200 day moving average is $5.78. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.66 and a quick ratio of 1.09. Ekso Bionics has a 1 year low of $2.73 and a 1 year high of $13.27. The firm has a market capitalization of $29.29 million, a P/E ratio of -1.97 and a beta of 0.80.

Insider Activity at Ekso Bionics

In other news, major shareholder Daniel Asher purchased 15,540 shares of the stock in a transaction dated Thursday, February 19th. The shares were purchased at an average price of $12.30 per share, with a total value of $191,142.00. Following the transaction, the insider owned 270,432 shares in the company, valued at $3,326,313.60. The trade was a 6.10% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in Ekso Bionics during the third quarter worth $198,000. Geode Capital Management LLC grew its holdings in shares of Ekso Bionics by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after purchasing an additional 10,281 shares during the period. Shay Capital LLC purchased a new position in shares of Ekso Bionics during the 3rd quarter worth $67,000. Finally, Virtu Financial LLC acquired a new stake in shares of Ekso Bionics during the 3rd quarter worth about $57,000. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EKSO has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ekso Bionics in a research report on Monday, December 22nd. HC Wainwright lowered shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. Finally, Wall Street Zen upgraded shares of Ekso Bionics to a “hold” rating in a research note on Saturday, December 13th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $10.50.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.